Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access — Oct 16th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventat...

Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week — Oct 14th, 2024

It might be of some concern to shareholders to see the Myriad Genetics, Inc. (NASDAQ:MYGN) share price down 13% in the last month. But that doesn't change the reality that over twelve months the stock has done really well. After all, the share price is up a market-beating 61% in that time....

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration — Oct 15th, 2024

Myriad Genetics, Inc. Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collabor...

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week — Oct 14th, 2024

It might be of some concern to shareholders to see the Myriad Genetics, Inc. (NASDAQ:MYGN) share price down 13% in the last month. But that doesn't change the reality that over twelve months the stock has done really well. After all, the share price is up a market-beating 61% in that time....

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer — Oct 8th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in br...

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer — Oct 8th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in br...

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration — Oct 15th, 2024

Myriad Genetics, Inc. Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collabor...

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access — Oct 16th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventat...

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access — Oct 16th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventat...

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week — Oct 14th, 2024

It might be of some concern to shareholders to see the Myriad Genetics, Inc. (NASDAQ:MYGN) share price down 13% in the last month. But that doesn't change the reality that over twelve months the stock has done really well. After all, the share price is up a market-beating 61% in that time....

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests — Oct 11th, 2024

Myriad Genetics, Inc. MYGN recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics....

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests — Oct 11th, 2024

Myriad Genetics, Inc. MYGN recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics....

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer — Oct 8th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in br...

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week — Oct 14th, 2024

It might be of some concern to shareholders to see the Myriad Genetics, Inc. (NASDAQ:MYGN) share price down 13% in the last month. But that doesn't change the reality that over twelve months the stock has done really well. After all, the share price is up a market-beating 61% in that time....

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration — Oct 15th, 2024

Myriad Genetics, Inc. Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collabor...

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer — Oct 8th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in br...

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer — Oct 8th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in br...

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access — Oct 16th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventat...

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration — Oct 15th, 2024

Myriad Genetics, Inc. Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collabor...

Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...

Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests — Oct 11th, 2024

Myriad Genetics, Inc. MYGN recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics....

Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...

Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...

Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week — Oct 14th, 2024

It might be of some concern to shareholders to see the Myriad Genetics, Inc. (NASDAQ:MYGN) share price down 13% in the last month. But that doesn't change the reality that over twelve months the stock has done really well. After all, the share price is up a market-beating 61% in that time....

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests — Oct 11th, 2024

Myriad Genetics, Inc. MYGN recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics....

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access — Oct 16th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventat...

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer — Oct 8th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in br...

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration — Oct 15th, 2024

Myriad Genetics, Inc. Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collabor...

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access — Oct 16th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventat...

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week — Oct 14th, 2024

It might be of some concern to shareholders to see the Myriad Genetics, Inc. (NASDAQ:MYGN) share price down 13% in the last month. But that doesn't change the reality that over twelve months the stock has done really well. After all, the share price is up a market-beating 61% in that time....

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week — Oct 14th, 2024

It might be of some concern to shareholders to see the Myriad Genetics, Inc. (NASDAQ:MYGN) share price down 13% in the last month. But that doesn't change the reality that over twelve months the stock has done really well. After all, the share price is up a market-beating 61% in that time....

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration — Oct 15th, 2024

Myriad Genetics, Inc. Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collabor...

Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests — Oct 11th, 2024

Myriad Genetics, Inc. MYGN recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics....

Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration — Oct 15th, 2024

Myriad Genetics, Inc. Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collabor...

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access — Oct 16th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventat...

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week — Oct 14th, 2024

It might be of some concern to shareholders to see the Myriad Genetics, Inc. (NASDAQ:MYGN) share price down 13% in the last month. But that doesn't change the reality that over twelve months the stock has done really well. After all, the share price is up a market-beating 61% in that time....

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access — Oct 16th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventat...

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration — Oct 15th, 2024

Myriad Genetics, Inc. Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collabor...

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests — Oct 11th, 2024

Myriad Genetics, Inc. MYGN recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics....

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer — Oct 8th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in br...

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests — Oct 11th, 2024

Myriad Genetics, Inc. MYGN recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics....

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests — Oct 11th, 2024

Myriad Genetics, Inc. MYGN recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics....

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer — Oct 8th, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in br...

Myriad Genetics Shares Fall Despite Partnership With jscreen — Oct 18th, 2024

Myriad Genetics, Inc. MYGN has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations. This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRis...